MOUHAMMED A HABRA to Protein Kinase Inhibitors
This is a "connection" page, showing publications MOUHAMMED A HABRA has written about Protein Kinase Inhibitors.
Connection Strength
0.474
-
Lenvatinib: Role in thyroid cancer and other solid tumors. Cancer Treat Rev. 2016 Jan; 42:47-55.
Score: 0.182
-
Treatment-emergent hypertension and efficacy in the phase 3 Study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT). Cancer. 2018 06 01; 124(11):2365-2372.
Score: 0.054
-
Association between new-onset hypothyroidism and clinical response in patients treated with tyrosine kinase inhibitor therapy in phase I clinical trials. Cancer Chemother Pharmacol. 2016 07; 78(1):167-71.
Score: 0.047
-
Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015 Feb 12; 372(7):621-30.
Score: 0.043
-
Efficacy and tolerability of different starting doses of sorafenib in patients with differentiated thyroid cancer. Oncologist. 2014 May; 19(5):477-82.
Score: 0.041
-
Role of salvage targeted therapy in differentiated thyroid cancer patients who failed first-line sorafenib. J Clin Endocrinol Metab. 2014 Jun; 99(6):2086-94.
Score: 0.040
-
The noninvestigational use of tyrosine kinase inhibitors in thyroid cancer: establishing a standard for patient safety and monitoring. J Clin Endocrinol Metab. 2013 Jan; 98(1):31-42.
Score: 0.037
-
Correlation of Performance Status and Neutrophil-Lymphocyte Ratio with Efficacy in Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Lenvatinib. Thyroid. 2021 08; 31(8):1226-1234.
Score: 0.017
-
Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma. J Immunother Cancer. 2018 07 11; 6(1):68.
Score: 0.014